Enveric Biosciences (NASDAQ:ENVB) Stock Breaks Above 50 Day Moving Average – Here’s Why

Posted by Brenda Bartman on Nov 4th, 2026

Shares of Enveric Biosciences, Inc. (NASDAQ:ENVB – Get Free Report) crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $1.46 and traded as high as $1.51. Enveric Biosciences shares last traded at $1.50, with a volume of 43,268 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Enveric Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

View Our Latest Stock Report on ENVB

Enveric Biosciences Stock Performance

The company’s fifty day moving average price is $1.46 and its 200-day moving average price is $2.00. The stock has a market cap of $6.72 million, a P/E ratio of -0.12 and a beta of 1.23.

Enveric Biosciences (NASDAQ:ENVB – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.76) EPS for the quarter.

Hedge Funds Weigh In On Enveric Biosciences

An institutional investor recently raised its position in Enveric Biosciences stock. StoneX Group Inc. grew its holdings in Enveric Biosciences, Inc. (NASDAQ:ENVB – Free Report) by 136.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,986 shares of the company’s stock after purchasing an additional 16,172 shares during the period. StoneX Group Inc. owned about 0.63% of Enveric Biosciences worth $41,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 13.82% of the company’s stock.

About Enveric Biosciences

(Get Free Report)

Enveric Biosciences, Inc is a biotechnology company focused on discovering and developing novel small-molecule therapeutics for cancer and central nervous system disorders. The company’s research uses insights from cannabinoid science and psychedelic-inspired compounds to identify potential treatments for conditions with significant unmet medical needs.

Enveric has developed a portfolio of proprietary drug candidates and intellectual property, including programs aimed at mental health conditions such as depression and other neurological disorders, as well as therapies intended to address cancer-related symptoms and supportive-care needs.